We are live on ! Find out more
MREO

Mereo BioPharma
MREO

Fund managers haven’t disclosed any holdings of MREO yet.

MREO Hedge Fund Activity: Q1 2026 in Review

63 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2026, worth a combined $24.9M — down 3.7% from $25.8M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of MREO and 15 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 15 added.

The largest buyer was Bank of America, adding an estimated $3.51M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $2.54M sold.

  • 63 institutional investors held Mereo BioPharma (MREO) as of Q1 2026, down from 70 in Q4 2025.
  • Funds reported $24.9M of Mereo BioPharma stock for Q1 2026, down 3.7% quarter-over-quarter.
  • 15 funds opened new Mereo BioPharma positions in Q1 2026 and 21 closed out, a net change of -6 holders.
  • The largest Mereo BioPharma buyer in Q1 2026 was Bank of America, an estimated $3.51M added.
  • The largest Mereo BioPharma seller in Q1 2026 was Schonfeld Strategic Advisors, an estimated $2.54M sold.

Based on aggregated 13F filings for Q1 2026.